Objectives Systemic infusions of aldosterone cause an acute increase in systemic vascular resistance (SVR) in healthy subjects. It is not clear whether this is due to a direct effect on the vasculature or the result of increased sympathetic tone. We investigated the short-term effects of locally infused aldosterone on the forearm resistance bed.
Introduction
The long-term adverse consequences of aldosterone on the cardiovascular system in chronic heart failure (CHF) and hypertension have been well studied and documented.These include structural remodelling of the heart, and the large and resistance arteries, with increased collagen production. [1] [2] [3] [4] [5] [6] [7] [8] [9] This results in reduced cardiac and arterial distensibility. [10] [11] [12] The short-term effects of aldosterone on the vasculature are much less clear.
Two recent studies have shown that, following intravenous infusion of aldosterone, there is an acute increase in systemic vascular resistance (SVR) in healthy male subjects. 13, 14 It is unclear whether this is due to a direct (local) effect on the vasculature or to the effects of increased sympathetic tone, arising from the impairment of baroreflex function, which has been reported to occur acutely 15 following infusion of aldosterone. In this study, we examined the local acute effects of aldosterone on forearm resistance vessels in healthy male subjects.
Methods

Subjects
Nine healthy male volunteers (mean age 31±3.8 years) were studied. None had a history of, or risk factors for, cardiovascular disease. None were taking any medications. All had normal resting biochemical parameters ( Table 1 ). The study was approved by the Local Research Ethics Committee, and all volunteers provided written informed consent.
Protocol
All studies were carried out in a quiet, temperature-controlled laboratory (21-23°C), in the afternoon to avoid the morning surge of aldosterone and cortisol. The subjects lay supine for 30 minutes prior to all measurements. Both forearms were cannulated with 18-gauge intravenous cannulae, and blood samples were taken from both , mounted onto an epidural catheter with dental wax, was inserted into the brachial artery of the non-dominant arm. Arterial blood pressure (BP) was continuously monitored by finger photo-plethysmography (TNO-TPD Biomedical Instrumentation, Amsterdam, Netherlands). Forearm blood flow (FBF) was measured in both arms using conventional strain gauge plethysmography (Hokanson, Bellevue, WA, USA). In brief, mercury in silastic strain gauges were placed over the widest circumference of the forearm (usually 3-5 cm below the antecubital crease) and congesting BP cuffs, connected to a rapid cuff inflator (Hokanson E20), were attached to both upper arms. The upper arm cuffs were inflated by the rapid cuff inflator to 40 mmHg for 10 seconds in every 15 seconds, after exclusion of the hands from circulation by wrist cuffs inflated to 50 mmHg above systolic BP (SBP). Standard surface ECG, beat-to-beat BP from the finger plethysmograph and FBF measurements were fed to an AcqKnowledge multi-channel data acquisition system (Biopac Systems, Goleta CA, USA) interfaced to a REM computer. FBF was calculated from the mean of three consecutive slopes with a coefficient of variation <5%, and expressed in ml/minute/ 100 ml forearm volume. The statistical power to detect a 10% reduction in FBF was >95%. Foreman vascular resistance (FVR) was calculated as; FVR = mean arterial blood pressure/FBF, expressed in resistance units. After resting measurements following a 10-minute saline infusion, aldosterone was infused incrementally at 10, 50, and 100 ng/minute. FBF measurements were performed after 10 minutes at each infusion rate. Venous blood samples were collected from each arm at the end of each infusion, for measurement of plasma aldosterone concentration.
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Results
Plasma aldosterone levels in the venous effluent of the infused arm increased in a dose-dependent fashion, from 113.3±17.9 pg/ml at baseline to 297.8±51.8 pg/ml at 10 ng/minute aldosterone (p=<0.01 vs. baseline), 743.9±105.9 pg/ml at 50 ng/minute (p=<0.001 vs. baseline) and 1230.6±73.7 pg/ml at 100 ng/minute (p=<0.0005
vs. baseline). The levels in the control arm fell from 101.4±18.8 pg/ml at baseline to 66.1±9.4 pg/ml (p=0.09) at the end of the first infusion and then remained stable for the remainder of the study ( Table 2) . Mean arterial BP did not change from baseline (73.9±2.3 mmHg at baseline vs. 77.6±2.0 at 10 ng/minute and 75.6±8.4 mmHg at peak infusion). There was no significant change in FBF in the infused arm (2.62 ml/minute/100 ml at baseline vs. 2.72 ml/minute/100 ml at 10 ng/minute and 2.68 ml/minute/100 ml at the end of the peak infusion) or in the control arm (2.83 ml/minute/100 ml at baseline vs. 2.56 ml/minute/100 ml at 10 ng/minute and 2.46 ml/minute/100 ml at the highest dose). After correction for the changes in the control arm, the FBF in the infused arm increased by 3.9%±7.3% (p=NS) at 10 ng/minute and by 4.1%±10.3% (p=NS) at peak infusion. Corrected FVR decreased by 6.8%±5.9% (p=NS) at 10 ng/minute and increased by 4.3%±11.3 (p=NS) at peak infusion. The results are summarised in Figure 1 . in forearm vascular tone. Aldosterone exerts its effects via at least two pathways at the cellular level. The genomic path is relatively slow and involves the activation of the mineralocorticoid receptor and subsequent alterations in gene expression. Effects of aldosterone on epithelial Na + /H + transport via the genomic pathway usually take 6 hours to peak, with a lag period of at least 30-60 minutes. 16 By contrast, non-genomic effects appear almost immediately. There has been some controversy regarding the involvement of the mineralocorticoid receptor in the non-genomic pathway, but it is now believed that these immediate effects are mediated via the special membrane resident mineralocorticoid receptor, which binds aldosterone and not glucocorticoids, 16, 17 because of the presence of the 'gate keeper' enzyme, 11β hydroxylase. 18 These fast, nongenomic actions of aldosterone have been demonstrated in many in vitro studies. Aldosterone regulates epithelial Na + /H + exchange via both genomic and non-genomic pathways. 19, 20 Vascular smooth muscle cell intra-cellular cAMP levels 21 and Ca 2+ levels 22 are elevated within minutes of exposure to aldosterone, implying that these effects occur by the fast, non-genomic route. Intravenous boluses of aldosterone have been shown to cause an immediate increase in SVR in healthy males. 13, 23 As aldosterone administration in these studies was systemic, it is unclear whether this was a result of a direct (local) acute vascular effect of aldosterone or an indirect vascular effect arising from sympathovagal imbalance. 24 This study focused on the immediate effects of local infusion of aldosterone on the forearm resistance bed. The doses administered resulted in plasma aldosterone levels in the venous effluent of the infused arm similar to those seen in severe chronic heart failure and severe primary hyperaldosteronism, while in the control arm, plasma aldosterone levels fell slightly (most likely a consequence of recumbency).Therefore, it is unlikely that aldosterone had any systemic effect during the study, providing the opportunity to compare the two arms.
Discussion
We conclude that it is unlikely that a direct local effect on the vasculature was responsible for the previously reported acute increase in SVR following systemic administration of aldosterone in healthy subjects, 13, 14 unless the local effects of aldosterone are selective for certain vascular beds, and not for others including the forearm resistance bed. Our data do not exclude a delayed effect of aldosterone (>2 hours) due to genomic mechanisms. Our study design does not allow us to define the mechanism of the increase in SVR observed by Wehling et al. 13, 14 However, it is possible that changes in sympathetic tone may be responsible. Aldosterone has been shown to impair baroreflex sensitivity via an effect on baroreceptor nerve endings, which is mediated via release of an endothelium-dependent mediator. 25 
